SPECIAL NOTICE
99 -- TECHNOLOGY/BUSINESS OPPORTUNITY FLASH Radiotherapy Accelerator
- Notice Date
- 4/5/2023 8:29:24 PM
- Notice Type
- Special Notice
- NAICS
- 334517
— Irradiation Apparatus Manufacturing
- Contracting Office
- LLNS � DOE CONTRACTOR Livermore CA 94551 USA
- ZIP Code
- 94551
- Solicitation Number
- IL-13639andIL-13640
- Response Due
- 5/5/2023 12:00:00 AM
- Archive Date
- 05/20/2023
- Point of Contact
- Genaro Mempin, Phone: 9254231121, Charlotte Eng, Phone: 9254221905
- E-Mail Address
-
mempin1@llnl.gov, eng23@llnl.gov
(mempin1@llnl.gov, eng23@llnl.gov)
- Description
- Opportunity: Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration to further develop its FLASH Radiotherapy Accelerator. Background: Studies published in the past few years show that high radiation dose rates over short periods of time may improve cancer therapy.� Called �FLASH Radiotherapy� or �FLASH-RT�, the method causes less damage to healthy tissue than lower radiation doses given over a longer period of time.� This technique requires controlling not only the total dose, but also the dose rate.� LLNL researchers have developed the technology that can control the dose rate that is high enough to kill cancer cells, yet short enough to avoid damaging healthy cells. Description: LLNL�s approach is to use their patented Photoconductive Charge Trapping Apparatus (U.S. Patent No. 11,366,401) as the active switch needed to discharge voltage across a vacuum gap in a particle accelerator, like the one described in their other patent (U.S. Patent No. 7,710,051).� These active switches enable adjusting the beam current, final energy, and temporal behavior of the particle beam.� The pulsed source for such a system can use the capacitors as described in LLNL�s U.S. Patent No. 10,270,368.� As the energy source for the FLASH-RT system, this technology promotes the use of a linear induction accelerator (LIA) utilizing the opticondistor (optical transconductance varistor) for ultrafast switching and control.� To achieve the required voltage for the accelerator cavities, the parallel charging series output switching configuration described in LLNL�s U.S. Patent No. 10,270,368 can be used. Researchers at LLNL have shown the potential for LIAs to deliver effective, targeted doses of �FLASH� radiation to cancer patients. The new technique can selectively kill cancer cells with minimal damage to healthy cells. Advantages/Benefits:� Less damage to healthy tissue � improved cancer therapy over conventional X-Ray therapy Applicable to Intensity-Modulated Radiation Therapy (IMRT) Applicable to a compact linear accelerator Potential Applications:� FLASH Radiotherapy (FLASH-RT) in the field of Radiation Oncology Development Status:� Current stage of technology development:� TRL 2 (Component and/or system concept formulated) LLNL has filed for patent protection on this invention. LLNL is seeking industry partners with a demonstrated ability to bring such inventions to the market. Moving critical technology beyond the Laboratory to the commercial world helps our licensees gain a competitive edge in the marketplace. All licensing activities are conducted under policies relating to the strict nondisclosure of company proprietary information.� Please visit the IPO website at https://ipo.llnl.gov/resources for more information on working with LLNL and the industrial partnering and technology transfer process. Note:� THIS IS NOT A PROCUREMENT.� Companies interested in commercializing LLNL's FLASH Radiotherapy Accelerator should provide a written statement of interest, which includes the following: 1.�������� Company Name and address. 2.�������� The name, address, and telephone number of a point of contact. 3.�������� A description of corporate expertise and/or facilities relevant to commercializing this technology. Written responses should be directed to: Lawrence Livermore National Laboratory Innovation and Partnerships Office P.O. Box 808, L-779 Livermore, CA� 94551-0808 Attention:�� IL-13639 and IL-13640 Please provide your written statement within thirty (30) days from the date this announcement is published to ensure consideration of your interest in LLNL's FLASH Radiotherapy Accelerator.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/caae908d49134dc5b1952c92f8355eec/view)
- Place of Performance
- Address: Livermore, CA, USA
- Country: USA
- Country: USA
- Record
- SN06640555-F 20230407/230405230103 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |